12 results
8-K
EX-99.1
CADL
Candel Therapeutics Inc
4 Apr 24
Candel Therapeutics Announces Positive Interim Data from Randomized Phase 2 Clinical Trial of CAN-2409 in Non-Metastatic Pancreatic Cancer
8:30am
-2409 is able to change the balance between the tumor and the patient’s anti-tumor immune response, which can convert progressive cancer into a chronic
10-K
2021 FY
CADL
Candel Therapeutics Inc
29 Mar 22
Annual report
8:46am
for the diagnosis, prevention, or treatment of a life-threatening, seriously debilitating or serious and chronic condition and when, without incentives
10-Q
szud7a3xcqj3v zwt
8 Sep 21
Quarterly report
8:37am
424B4
k14gg
28 Jul 21
Prospectus supplement with pricing info
4:02pm
S-1/A
knxcjyn
16 Jul 21
IPO registration (amended)
6:07am
S-1
gglyhqr2 0ffx
25 Jun 21
IPO registration
5:28pm
DRS/A
biaks8m72muz3z
31 Mar 21
Draft registration statement (amended)
12:00am
- Prev
- 1
- Next